Ongoing and upcoming clinical trials, such as the phase III trial investigating the effects of exenatide on individuals with mild cognitive impairment, might provide further insights into the therapeutic potential of GLP-1 agonists in treating dementia. This evidence concerns the gene GLP1R and dementia.